Clinical Mass Spectrometry is an analytical technique used in diagnosis and treatment of diseases. It helps identify biomarkers from samples such as blood, urine or tissues quickly and accurately, providing insight into disease states.

Market key trends:
Automated Imaging Mass Spectrometry (IMS) is emerging as an important technique for clinical and biomedical applications. IMS enables visualization of molecular distribution directly from tissue sections without sample preparation. It covers a wide range of applications such as cancer diagnosis, neurodegenerative diseases and metabolic disorders. The ability to gather molecular information directly from tissue morphologies with high sensitivity and specificity makes IMS a powerful clinical tool over the forecast period.

The global Clinical Mass Spectrometry Market is estimated to be valued at US$ 6.37 Bn in 2023 and is expected to exhibit a CAGR of 26.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Segment Analysis
The clinical mass spectrometry market has been segmented into technology, application, end user, and region. Based on technology, the market has been segmented into hybrid mass spectrometry, single mass spectrometry, and other technologies. The hybrid mass spectrometry segment is expected to dominate the market due to its enhanced capabilities for quantitative analysis and high-resolution detection abilities.

Key Takeaways
The global clinical mass spectrometry market is expected to witness high growth, exhibiting a CAGR of 26% over the forecast period, due to increasing demand for medical diagnosis procedures.

Regionally, North America is expected to dominate the clinical mass spectrometry market during the forecast period. This is attributed to presence of major market players and growing research and development activities in the region. Asia Pacific is expected to witness the highest growth rate over the forecast period.

Key players operating in the clinical mass spectrometry market are SCIEX AB(US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Bruker Corporation (US), Analytik Jena (Germany), JEOL Ltd. (Japan), Hiden Analytical (UK), and MKS Instruments (US), among others. Hybrid mass spectrometry systems by major players such as SCIEX, Thermo Fisher Scientific and others dominate the market.